Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,526.00
Bid: 1,525.50
Ask: 1,526.00
Change: -73.50 (-4.60%)
Spread: 0.50 (0.033%)
Open: 1,503.50
High: 1,532.00
Low: 1,484.00
Prev. Close: 1,599.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's FTSE edges down ahead of growth data, RBS soars

Fri, 25th Jul 2014 08:19

* FTSE 100 down 0.1 pct, investor sentiment muted onearnings

* Q2 GDP data in focus after IMF upgrades

* RBS jumps 14 pct, biggest one-day gain in four years

* BSkyB deal hits shares, Burberry weaker on LVMH

LONDON, July 25 (Reuters) - UK shares edged lower in earlytrading on Friday, ahead of second quarter GDP data, asinvestors digested a raft of corporate results and Royal Bank ofScotland enjoyed an unexpected pop from earnings.

Investor sentiment was muted across Europe, held back bydisappointing earnings on both sides of the Atlantic and by athird consecutive monthly fall in the widely followed German Ifosurvey of business sentiment.

Merger activity also dominated early trading, with BSkyB agreeing to pay 4.9 billion pounds ($8.3 billion) incash to buy Rupert Murdoch's pay-TV assets in Germany and Italy.Construction companies Balfour Beatty and Carillion rallied after confirming merger talks.

The FTSE 100 index was down 0.1 percent, slightly betterthan Germany's DAX and the French CAC 40, whilethe pan-European FTSEurofirst 300 was down 0.2 percent.

A preliminary reading of second quarter British grossdomestic product was in focus after the International MonetaryFund this week upgraded its forecasts for the UK economy.

"Today's first iteration of Q2 GDP could well be a goodindicator of how well the UK economy is shaping up for the restof the year," CMC Markets analyst Michael Hewson said.

Shares of RBS soared 14.5 percent, their biggest intradaygain in at least four years, after the lender released earningsa week early that were much better than expected.

Network operator Vodafone was also up 2.2 percentafter saying its performance had begun to stabilise in severalEuropean markets even as a slowdown in Spain and South Africaled to another heavy drop in its key revenue measure.

Meanwhile, BSkyB fell 2.4 percent, the worst performer onthe FTSE 100, with traders citing the placement of sharesrepresenting around 10 percent of the company's capital to helppay for its announced asset purchases.

Burberry fell 1.9 percent after French luxury goodsgroup LVMH posted below-forecast second quarter salesand profits, hit by a drop in demand from China.

Another heavy faller was drugmaker GlaxoSmithKline,down 1.8 percent. The company faces new allegations ofcorruption, this time in Syria, where the drugmaker and itsdistributor have been accused of paying bribes to securebusiness, according to a whistleblower's email.

Publisher Pearson posted a 41 percent slump infirst-half profit, reflecting increased restructuring charges,currency movements and phasing in of revenues into the secondhalf, though an increased dividend helped the stock tradehigher. (Reporting by Lionel Laurent; Editing by Catherine Evans)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.